Digene pulls out of deal with Cytyc
This article was originally published in Clinica
HPV diagnostic company Digene has called off its merger with Cytyc, a week after the US Federal Trade Commission (FTC) warned it intended to block the deal citing anti-trust issues in a highly concentrated market. Under the agreement, either company could terminate the stock and cash merger - originally valued at $554m - if the transaction was not carried out on or before June 28. Shares in Cytyc dropped 32 cents to $7.30, while shares in the much smaller Digene fell by around 21% to $9.30.
You may also be interested in...
FDA's Emergency Use Authorization for Malaria Drugs Could Hinder Trials of Other COVID-19 Treatments
Questions linger about the role the White House played in pushing the EUA, which comes with large product donations from Bayer and Sandoz that are expected to alleviate supply chain pressures for the drugs.
FDA Commissioner Stephen Hahn was added to the White House's pandemic task force as the outbreak grew, but he remained in a background role. That all changed the morning of 18 March, when President Trump tweeted: “I will be having a news conference today to discuss very important news from the FDA concerning the Chinese Virus!” A day later, Hahn was standing with Trump at the podium for the now-daily press briefings on Covid-19.
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.